Last updated: May 18, 2026
Top immune peptides
1. Thymosin Alpha-1 (Tα1, Thymalfasin)
28-amino-acid peptide derived from thymus tissue. Activates Toll-like receptor signaling and dendritic cell function. Brand name Zadaxin — approved in 30+ countries for hepatitis B, hepatitis C, and as immunotherapy adjunct in cancer. Not FDA-approved in US but available via compounding.
2. LL-37 (Cathelicidin)
37-amino-acid antimicrobial peptide produced by neutrophils and epithelial cells. Direct antimicrobial activity plus immunomodulation. Studied for wound infections, antibiotic-resistant bacteria, autoimmune conditions.
3. Thymalin
Khavinson thymic peptide bioregulator. Studied for immune restoration in aging populations. Reported reduced mortality and improved immune function in Khavinson cohort studies.
4. BPC-157
Body Protection Compound-157 has notable anti-inflammatory effects beyond tissue repair. Reduces inflammation in models of colitis, gastric damage, and systemic inflammation.
5. Vilon (Khavinson dipeptide)
Lys-Glu dipeptide bioregulator. Studied for immune function and longevity. Limited but interesting data.
6. Thymopentin (TP-5)
5-amino-acid synthetic fragment of thymopoietin. Older immune modulator with various clinical applications.
Thymosin Alpha-1 mechanism in depth
Tα1 modulates multiple immune pathways:
- Dendritic cell activation via TLR9 and TLR2 signaling
- Th1 polarization — favors cellular immunity response
- NK cell activation — enhanced natural killer cell cytotoxicity
- T regulatory cell modulation
- Apoptosis regulation in stressed cells
Approved clinical uses internationally
- Hepatitis B and C: As immunotherapy alongside antivirals
- HIV: Adjunctive immune support
- Cancer immunotherapy: Combination with chemotherapy in some countries
- Vaccine adjuvant: Enhances response in immunocompromised patients
COVID-19 research
During 2020-2022, Thymosin Alpha-1 was studied as an adjunctive treatment for COVID-19. Multiple small studies reported reduced mortality and ICU admissions. Larger trials were inconclusive. The drug is not approved for COVID indication.
Research dosing
- Thymosin Alpha-1: 1.6 mg subcutaneous, 2x weekly (standard clinical dose)
- LL-37: Limited human dosing data; topical formulations 0.1-1% are studied
- Thymalin: 10 mg sublingual or 1-2 mg intramuscular, 10-day cycles
Safety profile
Notable safety advantages: as immunomodulators rather than immunosuppressors, these peptides generally have favorable safety profiles. Most common side effects:
- Injection-site reactions
- Mild fatigue
- Theoretical concern: paradoxical autoimmune flare in patients with existing autoimmune conditions (caution)
Which immune peptide has the most evidence?<br />
Thymosin Alpha-1 has by far the largest body of published research and clinical use, including approval in 30+ countries for various indications.
Are these immunosuppressants?<br />
No — these peptides are immune modulators that generally enhance immune function. Different from steroids or immunosuppressants used for autoimmune disease.
Should I use these during illness?<br />
Acute use during established infection is studied for some peptides (Thymosin Alpha-1 specifically). Prophylactic use in healthy individuals is less well-supported.
Can these help with autoimmune conditions?<br />
Complicated. Thymosin Alpha-1 has been studied in some autoimmune contexts with mixed results. Theoretical concern about flaring autoimmunity exists. Discuss with rheumatologist before use in autoimmune disease.